zmz tirzepatide Trizepatide Learn more about Tirzepatide_Industry News_Senova

This is because tirzepatide is a relatively new medication, and clinical studies specifically involving breastfeeding mothers have not been conducted yet

Clinical evidence: The SURMOUNT-1 trial, published in the New England Journal of Medicine (2022), showed that participants receiving tirzepatide at the highest dose (15mg) lost an average of 22.5% of their body weight over 72 weeks roughly 52 pounds

Zepbound (tirzepatide) is a weekly injectable medication that is FDA approved for chronic weight management in overweight or obese adults, and to treat obstructive sleep apnea in adults with obesity

Since tirzepatide is designed to alter metabolism and cause weight loss, using it while pregnant could affect both the mother and the developing baby

Worldwide Delivery Click on a country below to view a guide on how to import medicine into that country.

Someone else dropped four dress sizes in three months